AstraZeneca to retire MedImmune brand amid restructuring

pharmafile | February 15, 2019 | News story | Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring 

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

The announcement comes just a month after AstraZeneca announced organisational changes which will see the creation of therapy area specific R&D units.

AstraZeneca acquired MedImmune in 2007, running the firm as a separate biologics unit. However the restructuring will see the company integrated into AstraZeneca’s new R&D units.

The changes will not affect MedImmune’s ongoing partnerships and collaborations. AstraZeneca did not offer insight as to whether the restructuring would result in changes to management; however a spokesperson suggested that no layoffs are expected.

 The news comes after a number of high profile resignations. Nevertheless recent figures show that  AstraZeneca’s fourth quarter revenue jumped 11% year on year, reaching $6.4 billion

“As we recently entered a new phase in our strategic development, we have refined our organisation to position ourselves for the next phase of our journey,” CEO Pascal Soriot said.

Louis Goss

Related Content


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Latest content